Literature DB >> 8477558

Protein binding and ivermectin estimations in patients with onchocerciasis.

P O Okonkwo1, J E Ogbuokiri, E Ofoegbu, U Klotz.   

Abstract

We measured ivermectin in plasma, urine, and saliva of nine patients with onchocerciasis. The aim was to establish pharmacokinetic parameters and to assess the most facile medium for use in monitoring compliance. Binding of ivermectin to plasma proteins in vitro was also investigated. The mean (+/- SEM) plasma values for the nine subjects were as follows: weight, 66.3 +/- 2.8 kg; dose, 11.11 +/- 0.4 mg; half-life, 56.50 +/- 7.01 hours; clearance, 142.5 +/- 22.6 L/kg; volume of distribution, 9.91 +/- 2.67 L/kg; area under the plasma concentration-time curve, 1545.3 +/- 190.5 ng/ml.hr; time to reach maximum concentration, 4.7 +/- 0.5 hours; and maximum concentration, 38.2 +/- 5.8 ng/ml. Ivermectin was not detected in the urine of any of the nine subjects. Low levels were found in saliva. Blood specimens remain the only reliable biologic fluid for assessment of compliance after ivermectin oral administration. Ivermectin binds specifically to human serum albumin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8477558     DOI: 10.1038/clpt.1993.46

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.

Authors:  Sheila Annie Peters
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

2.  Patterns of doramectin tissue residue depletion in parasitized vs nonparasitized lambs.

Authors:  Rubén Pérez; Cristina Palma; Maria José Nuñez; Ignacio Cabezas
Journal:  Parasitol Res       Date:  2008-01-16       Impact factor: 2.289

Review 3.  The pharmacokinetics and interactions of ivermectin in humans--a mini-review.

Authors:  Aránzazu González Canga; Ana M Sahagún Prieto; M José Diez Liébana; Nélida Fernández Martínez; Matilde Sierra Vega; Juan J García Vieitez
Journal:  AAPS J       Date:  2008-01-25       Impact factor: 4.009

4.  Ivermectin levels in human breastmilk.

Authors:  J E Ogbuokiri; B C Ozumba; P O Okonkwo
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Ivermectin levels in human breast milk.

Authors:  J E Ogbuokiri; B C Ozumba; P O Okonkwo
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 6.  Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review.

Authors:  Luka Verrest; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

Review 7.  Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents.

Authors:  Valentin Al Jalali; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

8.  Effect of Ivermectin Treatment on the Frequency of Seizures in Persons with Epilepsy Infected with Onchocerca volvulus.

Authors:  Alfred Dusabimana; Solomon Tsebeni Wafula; Stephen Jada Raimon; Joseph Nelson Siewe Fodjo; Dan Bhwana; Floribert Tepage; Gasim Abd-Elfarag; An Hotterbeekx; Steven Abrams; Robert Colebunders
Journal:  Pathogens       Date:  2020-12-31

Review 9.  Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.

Authors:  Nicolas Venisse; Gilles Peytavin; Stephane Bouchet; Marie-Claude Gagnieu; Rodolphe Garraffo; Romain Guilhaumou; Caroline Solas
Journal:  Antiviral Res       Date:  2020-07-10       Impact factor: 5.970

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.